

Key Performance Indicators to assign specific monitoring for SEL COVID-19 medicines for non-hospitalised patients and COVID-19 medicines for hospitalised patients

Up until April 2023, treatments for COVID-19 infection were under the remit of NHS England (NHSE). From April 2023 the commissioning responsibility for all COVID-19 treatments was transferred from NHSE to Integrated Care Boards (ICBs). Previous key metrics collated by NHSE can be found in the legacy Commissioning Framework: COVID-19 Therapeutics for Non-Hospitalised Patients [C1677-commissioning-framework-covid-19-therapeutics-for-non-hospitalised-patients-march-23.pdf](https://www.england.nhs.uk/media/126777/c1677-commissioning-framework-covid-19-therapeutics-for-non-hospitalised-patients-march-23.pdf) (england.nhs.uk).

At present the COVID-19 medicines Delivery Unit provides the service for non-hospitalised patients. This monitoring framework outlines the parameters that will be measured during this period. The parameters focus on the use of medicines in line with existing guidance from NICE and legacy NHSE documents, as reflected in the [SEL Joint Medicines Formulary](#).

SEL Forum for antimicrobial stewardship: June 2025

SEL Integrated Medicines Optimisation Committee: August 2025

Approval date: August 2025

Next review date: April 2026 (or sooner if evidence or practice changes)

Not to be used for commercial or marketing purposes. Strictly for use within the NHS

Key outcomes measures for non-hospitalised patients

KPI	Intervention	Standard	Measure and frequency	Data Source	Who measures	Frequency of reporting – in any financial year
1	Review number of patients receiving each COVID-19 treatment	<i>N/A – baseline data to assess proportions accessing each treatment option.</i>	Total number of patients receiving each COVID-19 treatment as a proportion of the total number of patients receiving COVID-19 treatments	Trust database	Trust	Six monthly: <ul style="list-style-type: none"> First report to be presented at October SELFAS (H1 data) Second report to be presented at April SELFAS (H2 data)
2	All patients to be considered for treatment in line with NICE Guideline (NG)191* Recommendations or agreed local arrangements *NG191 incorporates NICE Technology Appraisals published for COVID-19 treatments	All patients receive treatments in line with NICE recommendations 100% of patients audited should be receiving treatment in line with NG191 criteria or agreed local arrangements (treatment up to 7 days of symptom onset – off-label) Audit should also cover treatments not recommended by NICE.	a) Audit of patients treated in line with NG191 approved COVID-19 treatments. b) Audit of patients treated under agreed local arrangements (treatment up to 7 days of symptom onset – off-label) c) For patients not treated in line with NG191 or agreed local arrangements – rationale for variance to be explored. Audits will cover all patients over the reporting period.	Trust database	Trust	Six monthly: <ul style="list-style-type: none"> First report to be presented at October SELFAS (H1 data) Second report to be presented at April SELFAS (H2 data)
3	Review number of patients receiving treatment who are registered with SEL GP vs non-SEL patients	<i>N/A – baseline data to assess proportions accessing treatment.</i>	Audit number of non-SEL patients prescribed treatments* *treatments provided by SEL CMDU based at Guy's Hospital only	IDEA (SEL CMDU patients only)	Guy's Hospital only	Six monthly: <ul style="list-style-type: none"> First report to be presented at October SELFAS (H1 data) Second report to be presented at April SELFAS (H2 data)

Key outcome measures for COVID-19 treatments in hospitalised patients

KPI	Intervention	Target	Measure and frequency	Data Source	Who measures	Frequency of reporting – in any financial year
1	Review number of patients receiving each COVID-19 treatment	<i>N/A – baseline data to assess proportions accessing each treatment option.</i>	Total number of patients receiving each COVID-19 treatment as a proportion of the total number of patients receiving COVID-19 treatments	Trust database	Trust	Six monthly: <ul style="list-style-type: none"> First report to be presented at October SELFAS (H1 data) Second report to be presented at April SELFAS (H2 data)
2	<p>All patients to be considered for treatment in line with *NG191 recommendations or agreed local arrangements</p> <p>*NG191 incorporates NICE Technology Appraisals published for COVID-19 treatments</p>	<p>All patients receive treatments in line with NICE recommendation and</p> <p>100% of patients audited should be receiving treatment in line with NG191 criteria or agreed local arrangements (treatment up to 7 days of symptom onset – off-label)</p> <p>Audit should also cover treatments not recommended by NICE.</p>	<p>a) Audit of patients treated in line with NG191 approved COVID-19 treatments.</p> <p>b) Audit of patients treated under agreed local arrangements (treatment up to 7 days of symptom onset – off-label)</p> <p>c) For patients not treated in line with NG191 or agreed local arrangements – rationale for variance to be explored.</p> <p>Audits will cover all patients over the reporting period.</p>	Trust database	Trust	Six monthly: <ul style="list-style-type: none"> First report to be presented at October SELFAS (H1 data) Second report to be presented at April SELFAS (H2 data)

For use of COVID-19 medicines in both settings:

1	Measure impact on overall medicines costs to ensure value for money for commissioning arrangements	High cost drugs use (Biologics) in SEL ICB	Six monthly breakdown of treatments used and cost	Acute activity	SEL ICB Business Intelligence	To be reviewed by SEL FAS 6 monthly
---	--	--	---	----------------	-------------------------------	-------------------------------------

Approved by: SEL Forum for Antimicrobial Stewardship June 2025, SEL IMOC: August 2025

Review date: April 2026